Picture of Neurizon Therapeutics logo

NUZ — Neurizon Therapeutics Cashflow Statement

0.000.00%
au flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapMomentum Trap

Annual cashflow statement for Neurizon Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.

2022
June 30th
2023
June 30th
2024
June 30th
2025
June 30th
2026
June 30th
Period Length:12 M12 M12 M12 M12 M
Source:ARSARSARSARSARS
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Changes in Working Capital1.131.080.8671.96.16
Other Operating Cash Flow
Cash from Operating Activities-1.33-1.56-5.17-14.3-15.1
Capital Expenditures-0.043-0.0350-0.002-0.008
Purchase of Fixed Assets
Other Investing Cash Flow Items0-0-1.17-0.020
Acquisition of Business
Sale of Business
Sale/Maturity of Investment
Purchase of Investments
Change in Net Intangibles
Other Investing Cash Flow
Cash from Investing Activities-0.043-0.035-1.17-0.022-0.008
Financing Cash Flow Items——0.035-0.0350
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities0.7711.8913.38.7623.5
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-0.6050.297.01-5.558.53